Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Vanda Pharmaceuticals Inc. (VNDA)’s Stock Jumps Following NDA Approval

Page 1 of 2

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA)’s shares have advanced by more than 9% after the U.S. Food and Drug Administration approved Vanda’s supplemental New Drug Application for expanding the prescribing information to include the effectiveness of Fanapt as a maintenance treatment for schizophrenia in adults. Fanapt is an atypical antipsychotic agent indicated for the treatment of schizophrenia. Expanding the use of Vanda will lead to more sales and potentially more cash flow. The FDA is also currently reviewing the company’s application for three years of marketing exclusivity based upon the expansion now approved in the supplemental New Drug Application.

This is definitely good news for investors, although Vanda Pharmaceuticals is not very popular among them and the stock was in just 22 hedge funds’ portfolios at the end of the first quarter of 2016, up by one fund over the quarter. However, the level and the change in hedge fund popularity aren’t the only variables you need to analyze to decipher hedge funds’ perspectives. A stock may witness a boost in popularity but it may still be less popular than similarly priced stocks. That’s why at the end of this article we will examine companies such as Agenus Inc (NASDAQ:AGEN), First Foundation Inc (NASDAQ:FFWM), and Carriage Services, Inc. (NYSE:CSV) to gather more data points.

Follow Vanda Pharmaceuticals Inc. (NASDAQ:VNDA)
Trade (NASDAQ:VNDA) Now!

If you’d ask most investors, hedge funds are perceived as underperforming, old financial vehicles of years past. While there are more than 8000 funds in operation today, Our researchers look at the masters of this club, about 700 funds. These investment experts orchestrate bulk of the smart money’s total capital, and by tracking their matchless investments, Insider Monkey has deciphered various investment strategies that have historically outpaced Mr. Market. Insider Monkey’s small-cap hedge fund strategy defeated the S&P 500 index by 12 percentage points annually for a decade in their back tests.

Keeping this in mind, let’s go over the recent action regarding Vanda Pharmaceuticals Inc. (NASDAQ:VNDA).

When looking at the institutional investors followed by Insider Monkey, Deerfield Management, managed by James E. Flynn, holds the most valuable position in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA). Deerfield Management has a $50.1 million position in the stock, comprising 2.1% of its 13F portfolio. Coming in second is Palo Alto Investors, led by William Leland Edwards, holding a $33.7 million position; the fund has 2.6% of its 13F portfolio invested in the stock. Other peers with similar optimism include John Paulson’s Paulson & Co, Jeffrey Jay and David Kroin’s Great Point Partners and Israel Englander’s Millennium Management.

On the next page, we are going to take a closer look at some funds that initiated stakes in Vanda Pharmaceuticals during the first quarter.

Page 1 of 2

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...
X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!